AVITA Medical, Inc. Stock Australian S.E.

Equities

AVH

AU000000AVH4

Biotechnology & Medical Research

Market Closed - Australian S.E. 02:10:38 2024-07-04 am EDT 5-day change 1st Jan Change
2.37 AUD -0.42% Intraday chart for AVITA Medical, Inc. -2.07% -44.76%
Sales 2024 * 113M 76.2M Sales 2025 * 158M 106M Capitalization 301M 202M
Net income 2024 * -66M -44.4M Net income 2025 * -32M -21.53M EV / Sales 2024 * 2.34 x
Net cash position 2024 * 36.16M 24.32M Net Debt 2025 * 2.27M 1.53M EV / Sales 2025 * 1.93 x
P/E ratio 2024 *
-4.42 x
P/E ratio 2025 *
-9.91 x
Employees 207
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.08%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on AVITA Medical, Inc.

1 day-0.42%
1 week-2.07%
Current month-2.07%
1 month-17.42%
3 months-48.59%
6 months-40.00%
Current year-44.76%
More quotes
1 week
2.34
Extreme 2.34
2.47
1 month
2.34
Extreme 2.34
2.93
Current year
2.34
Extreme 2.34
5.62
1 year
2.34
Extreme 2.34
6.27
3 years
1.28
Extreme 1.28
6.27
5 years
1.28
Extreme 1.28
17.30
10 years
0.92
Extreme 0.92
17.30
More quotes
Date Price Change Volume
24-07-04 2.37 -0.42% 204 929
24-07-03 2.38 -0.83% 234,605
24-07-02 2.4 -1.64% 460,966
24-07-01 2.44 +0.83% 216,122
24-06-28 2.42 +0.41% 231,829

Delayed Quote Australian S.E., July 04, 2024 at 02:10 am EDT

More quotes
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
11.6 AUD
Average target price
34.91 AUD
Spread / Average Target
+200.94%
Consensus